BackgroundCerivastatin was the most potent statin until it was withdrawn from the market due to a number of fatalities due to rhabdomyolysis, however, the dose-related magnitude of e ect of cerivastatin on blood lipids is not known. Objectives Primary objectiveTo quantify the e ects of various doses of cerivastatin on the surrogate markers: LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides in children and adults with and without cardiovascular disease.The aim of this review is to examine the pharmacology of cerivastatin by characterizing the dose-related e ect and variability of the e ect of cerivastatin on surrogate markers. Secondary objectivesTo quantify the e ect of various doses of cerivastatin compared to placebo on withdrawals due to adverse e ects. To compare the relative potency of cerivastatin with respect to fluvastatin, atorvastatin and rosuvastatin for LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides. Search methodsThe Cochrane Hypertension Information Specialist searched the following databases for RCTs up to March 2019: CENTRAL (2019, Issue 3), Ovid MEDLINE, Ovid Embase, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov.We also searched the European Patent O ice, FDA.gov, and ProQuest Dissertations & Theses, and contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. Selection criteriaRCTs and controlled before-and-a er studies evaluating the dose response of di erent fixed doses of cerivastatin on blood lipids over a duration of three to 12 weeks in participants of any age with and without cardiovascular disease.

BackgroundCerivastatin was the most potent statin until it was withdrawn from the market due to a number of fatalities due to rhabdomyolysis, however, the dose-related magnitude of e ect of cerivastatin on blood lipids is not known. Objectives Primary objectiveTo quantify the e ects of various doses of cerivastatin on the surrogate markers: LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides in children and adults with and without cardiovascular disease.The aim of this review is to examine the pharmacology of cerivastatin by characterizing the dose-related e ect and variability of the e ect of cerivastatin on surrogate markers. Secondary objectivesTo quantify the e ect of various doses of cerivastatin compared to placebo on withdrawals due to adverse e ects. To compare the relative potency of cerivastatin with respect to fluvastatin, atorvastatin and rosuvastatin for LDL cholesterol, total cholesterol, HDL cholesterol and triglycerides. Search methodsThe Cochrane Hypertension Information Specialist searched the following databases for RCTs up to March 2019: CENTRAL (2019, Issue 3), Ovid MEDLINE, Ovid Embase, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov.We also searched the European Patent O ice, FDA.gov, and ProQuest Dissertations & Theses, and contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. Selection criteriaRCTs and controlled before-and-a er studies evaluating the dose response of di erent fixed doses of cerivastatin on blood lipids over a duration of three to 12 weeks in participants of any age with and without cardiovascular disease.